Quadrant Biosciences in the news
You likely know that we developed the world’s first epigenetic saliva test for autism, called Clarifi™ ASD. We’re excited to announce that we are currently working on a new rapid, simple saliva swab to diagnose the COVID-19 virus. Unlike other tests, this is a simple saliva swab that looks for the presence of the COVID-19 RNA strand, which has already been identified. We expect this test will help shorten the current diagnostic timeline. Stay tuned for updates by following us on social media @quadrantbiosciences.
Quadrant Biosciences Is Working On A COVID-19 Saliva Swab
CEO and Founder of Quadrant Biosciences, Rich Uhlig, talks about the company’s progress researching a new way to diagnose COVID-19, with a simple saliva swab.
Quadrant Biosciences Discusses Saliva Swab for COVID-19
Director of the research lab, Rhianna Ericson, explains the science behind the saliva swab for COVID-19, and how that can speed up the current diagnostic process.
Our aim is to develop solutions for important global health issues
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease and mTBI, through the application of the Clarifi™ epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. Clarifi ASD, an autism diagnostic aid, is the first product to launch commercially from this platform. Clarifi ASD is now available through prescription; details on how to obtain testing are available on Clarifi’s website.